ClinicalTrials.gg
Enrolling by invitationNCT06710626CONVOYUpdated Nov 13, 2026

Control of Assistive Devices Via Brain-Computer Interface Technology

An interventional study of Assistive Robotic Arm in Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS) and Quadriplegia, sponsored by Neuralink Corp. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Neuralink Corp · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Quadriplegia with a site in United States — 43 open to participants now, 50 under way, 2 of them phase 3. Quadriplegia · United States.

Planned enrollment
97th of 111
3 · median 14
Started
2024
with 7 others
No phase
82 of 122
33 open now
Primary completion
2031-05
later than 48 of 49 live
Registered
106th of 122
by date
Lead sponsor
4 of 122
Neuralink Corp

Among the 122 studies in Quadriplegia with a site in United States, this one is the 97th largest by planned enrollment of the 111 interventional ones that give a count, is one of 8 that started in 2024, is one of 82 with no phase, reaches primary completion later than 48 of the 49 other live ones, and was the 106th registered.

Quadriplegia

224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.

Browse Quadriplegia studies →

Open to participants now

43 of the 122 studies in Quadriplegia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Quadriplegia studies recruiting now, 17 (30%) set no upper age limit and 28 (49%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Quadriplegia with a site in United States, or all of them as a file.
02

Study summary

The CONVOY Study is a clinical trial designed to explore the feasibility of participants from the PRIME Study (NCT06429735) using the N1 Implant to control various assistive devices. The main goal is to determine whether participants can successfully modulate their brain activity to control devices, such as an Assistive Robotic Arm (ARA). This study will assess the effectiveness, consistency, and safety of neural control using the ARA and other assistive devices.

03

Conditions studied

  • Tetraplegia/Tetraparesis
  • Amyotrophic Lateral Sclerosis (ALS)
  • Quadriplegia
  • Spinal Cord Injury (SCI)
  • Spinal Cord Injury Cervical

Keywords

  • brain computer interface
  • robotic arm
  • assistive device
  • Neuralink N1 Implant
  • Neuralink
  • N1 Implant
  • ALS
  • Spinal cord injury
  • Quadriplegia
  • tetraplegia
  • Robot
  • external device control
  • neuroprosthetics
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Continued enrollment in the PRIME Study.
  • Implanted with the N1 Implant.

Exclusion criteria

Exclusion Criteria:

  • Explantation or deactivation of the N1 Implant.
  • Insufficient N1 Implant BCI performance demonstrated.
  • Lack of a suitable physical space to perform research sessions.
  • Any condition which, in the opinion of the Investigator, would compromise the candidate's ability to safely participate in the study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Other
    Single

    Device: Assistive Robotic Arm

Interventions

  • DeviceAssistive Robotic Arm

    The intervention involves using the N1 Implant, a wireless brain-computer interface (BCI), to enable participants to control the Assistive Robotic Arm through neural signals.

    Also known as: BCI controlled robotic arm

06

What researchers measure

Primary outcomes

  1. Ability of participants to modulate brain activity for controlling an assistive device via the N1 Implant.

    Time frame: 3-months following first use of the assistive device

Secondary outcomes

  1. Rate of Device-Related Adverse Events (AE)

    Time frame: Up to 72 months after enrollment

  2. Assessment of Quality of Life Using the Psychosocial Impact of Assistive Devices Scale (PIADS)

    Time frame: From enrollment, every 3 months, up to 72 months

  3. Change in Assistive Technology Device Predisposition Assessment (ATD PA) Score

    Time frame: From enrollment, every 3 months, up to 72 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2031, 78 months after the start.

Of 97 interventional studies with no phase under Quadriplegia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Nov 29, 2024
StartActual
Nov 25, 2024
Primary completionEst.
May 25, 2031
CompletionEst.
May 25, 2031
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06710626
Lead sponsor
Neuralink Corp
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Nov 25, 2024
Primary completion
May 25, 2031 (estimated)
Completion
May 25, 2031 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion